OncoAlert (@OncoAlert) header
OncoAlert (@OncoAlert) profile picture

🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°

Worldwide
Joined March 2019
Photo by OncoAlert (@OncoAlert)Photo by OncoAlert (@OncoAlert)Photo by OncoAlert (@OncoAlert)Photo by OncoAlert (@OncoAlert)Photo by OncoAlert (@OncoAlert)Photo by OncoAlert (@OncoAlert)Photo by OncoAlert (@OncoAlert)Photo by OncoAlert (@OncoAlert)Photo by OncoAlert (@OncoAlert)Photo by OncoAlert (@OncoAlert)
🎸 #UromigosLIVE 2026: the conversation on X 📊 THE FINAL NUMBERS Coverage by @OncoAlert 🚨 Nashville | Nov 13–14 🌍 5.7M potential reach 💬 3,200 posts & mentions 🔥 4,200 engagements 🇺🇸 USA 59.5% 🇮🇹 Italy 13.3% 🇪🇸 Spain 10% 🇮🇳 India 4.6% 🇯🇵 Japan 🇩🇪 Germany 🇸🇦 Saudi Arabia 🇦🇪 UAE 🇳🇱 Netherlands 🏆 Thank you to every #UroVoice who amplified the meeting, and to Tom & Brian for an unforgettable #UromigosLIVE 🙏 WE ARE ALL OncoAlert 🌐 Source: Talkwalker, X, Nov 10–16 @Uromigos @tompowles1 @brian_rini @shilpaonc @nataliagandur @PGrivasMDPhD @weoncologists @neerajaiims @Dr_Aggen @NazliDizman @montypal @AmandaNizamMD @scserendipity1 @DrKarineTawagi @CParkMD @TiansterZhang @OncoReporte @dralsharm @crisbergerot @UroDocAsh @RenoHemonc
1
6
1
11
1,584
OncoAlert retweeted
🎥 T-cell engagers in renal cell carcinoma: is the sun finally coming out? At #UromigosLive 2026 in Nashville, @tompowles1 and @brian_rini discuss the CD3 x ENPP3 bispecific data @montypal presented at #ESMO26 : 🔹 ENPP3 is expressed on most clear cell and papillary RCC 🔹 ORR ~45% in heavily refractory, PD-1-pretreated #RCC, across 3 active dose levels 🔹 Benefit seen regardless of prior HIF inhibitor or TKI therapy 🔹 Requires step-up dosing. Main toxicities are early CRS (doses 1–2) and rash, because ENPP3 is also on skin mast cells. Both look manageable 🔹 Still open: durability and ENPP3 expression as a biomarker Why has #kidneycancer lagged behind prostate cancer and SCLC on T-cell engagers, and how does it catch up? Possible next steps: combinations with PD-1, a move to frontline, and other targets like CD70. Plus a detour to the 1998 World Cup final ⚽ ⭐️MIBC session Friday 1pm CT: guoncologynow.com/videos/uro… ⭐️World Cup Final 🌐 3:30pm CT: guoncologynow.com/videos/uro… @Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan #OncoAlert #GUOnc #OncoX
12
5
27
4,884
📣 Registration Now Open for #IKCSNA26 Join us for the 2026 International Kidney Cancer Symposium (IKCS): North America, where a multidisciplinary community of leading experts from academia, clinical care, industry and advocacy come together to share ideas, explore emerging trends and shape the future of kidney cancer research and care. 🗓️ November 19–21, 2026 📍 Dallas, Texas 🏨 Renaissance Dallas Hotel Register 👉 kidneycancer.org/event/2026-… @KidneyCancer @LauraBukavinaMD @QingZhangLab @bergsa83 @mkbupathi @ADESAIONCMD @AmyLuckenbaugh @virajmaster @spsutkaMD @ChadTangMD @MVossMD @TiansterZhang @PavlosMsaouel @salvolarosa @GEVaughan1
379
Can ctDNA tell us who should get SBRT for oligoprogressive mCRPC? jamanetwork.com/journals/jam… Circulating Tumor DNA in Oligoprogressive Prostate Cancer Treated With Stereotactic Radiotherapy A Prespecified Secondary Analysis of a Nonrandomized Clinical Trial In this prespecified analysis of the phase 2 TRAP trial, 77 patients with oligoprogressive metastatic castration-resistant #ProstateCancer received SBRT while continuing an androgen receptor pathway inhibitor. ➡️Pre-SBRT ctDNA positivity was associated with significantly shorter progression-free survival: median 3.0 vs 7.8 months for ctDNA-negative patients. ✅These findings suggest ctDNA status may help identify patients most likely to benefit from SBRT while continuing ARPI therapy. @f_orlando_, @Dr_AJC, @nickva1, @y_suhughes, @FrancescaBZNY, @alison_tree, @AttardLab
6
13
790
🚨 73.8% response rate in advanced TNBC: promising early data for pumitamig + nab-paclitaxel. thelancet.com/journals/lanon… Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial In this phase 1b/2 trial, first-line pumitamig, an investigational PD-L1/VEGF-A bispecific antibody, plus nab-paclitaxel demonstrated encouraging activity in 42 patients with advanced or metastatic triple-negative #BreastCancer . ➡️ At 35.2 months’ median follow-up, the confirmed objective response rate was 73.8%, including one complete response. ➡️ Grade ≥3 toxicities included neutropenia, leukopenia, proteinuria, and febrile neutropenia. No treatment-related deaths occurred. ✅These findings support further evaluation in larger global trials.
1
4
9
598
🧬 Can urine EV glycan signatures help us distinguish aggressive prostate cancer from indolent disease BEFORE committing patients to biopsy? lnkd.in/exDkkJ4d Extracellular vesicle glycan profiling for pre-biopsy detection of prostate cancer Could urine extracellular vesicle (EV) glycan profiling improve #ProstateCancer detection beyond PSA? ➡️ In this study of 135 men, Glycoflow analysis of post-DRE urine EVs improved discrimination of clinically significant prostate cancer (AUC 0.80 vs 0.71–0.72) and very significant disease (0.81–0.82 vs 0.72–0.73) when combined with clinical parameters. ✅ EV glycan profiling provided complementary diagnostic information, potentially improving biopsy decisions and reducing overdiagnosis, pending larger validation. @sim1garz8 @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists
6
12
807
What if instead of simply inhibiting the androgen receptor, we could rewire the complex that drives its activity? nature.com/articles/s41586-0… Domain-alteration chimeras rewire oncogenic complexes in prostate cancer This study introduces DALTAC-1, a first-in-class domain-alteration chimera designed to rewire the androgen receptor (AR)–p300/CBP complex in metastatic castration-resistant #ProstateCancer . ➡️ By forcing a non-native interaction between AR and p300/CBP, DALTAC-1 locks the complex into a nonproductive state, profoundly suppressing AR-driven transcription. ✅The approach produced deep, durable tumor regressions across preclinical models while selectively targeting AR-dependent prostate cancer cells. @ArulChinnaiyan, @Chinnaiyanlab, @Pixel_and_Path, @abhijitparolia, @EyunniSanjana, @yuanyuan_qiao, @rahulmannan, @UMich @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists
1
9
13
816
OncoAlert retweeted
The eye can also be a target of immune activation. ICI ocular toxicity affects different ocular structures and may threaten vision. Early ophthalmologic recognition matters. JIPO p.190 innovationsjournals-jipo.kgl… @HajjarJoud @BettzyStephen @ANaingMD @AAO_ophth @OncoAlert #JIPO #ION
🤖 Made with AI
1
2
199
OncoAlert retweeted
At 6 months, the two curves looked the same! At 3 years: 53% vs 30% without progression. Pembrolizumab alone vs chemo, dMMR endometrial cancer. 🧬In dMMR endometrial cancer, what does chemo still add? @TheLancet @GOG @ESGO_society @OncoAlert @OpenMedicineHQ
2
2
325
OncoAlert retweeted
Can patients with muscle-invasive bladder cancer avoid radical cystectomy? From radical cystectomy to bladder-sparing approaches, the debate took center stage at #UromigosLive in Nashville 🎸 Listen to the full discussion ⬇️ 🎧 Apple: apple.co/4t9r8Ps 🎧 Spotify: bit.ly/4iPpf6Q
5
7
851
On November 17, 2026, the FDA 🇺🇸granted accelerated approval to neladalkib for adults with ALK-positive locally advanced or metastatic #NSCLC #LungCancer 🫁previously treated with alectinib, or with ≥2 ALK TKIs plus platinum chemotherapy. In the single-arm ALKOVE-1 trial, ORR was 49% after alectinib alone (n=67) and 32% after multiple TKIs and chemotherapy (n=155). Among responders, about half had responses lasting ≥12 months in both cohorts, offering a new option. Pinging Lung Cancer Faculty @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers
2
4
569
FDA grants accelerated approval to neladalkib (NVL-655) for advanced ALK positive NSCLC with prior TKI therapy. Based on ALKOVE-1 study - post alectinib RR 49%, more than half of responses ongoing at a year. Favorable tox profile. New best in class? fda.gov/drugs/cancer-approva…
3
15
2
48
3,991
OncoAlert retweeted
FDA approves giredestrant + everolimus for adults with ER+/HER2− ESR1-mutated locally advanced or metastatic #BreastCancer : 🔹 Recurrence during or after adjuvant endocrine therapy, OR
🔹 Progression on ≥1 endocrine-based regimen in the metastatic setting 🧬 FoundationOne Liquid CDx is authorized as the companion diagnostic to detect ESR1 mutations fda.gov/drugs/cancer-approva… @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76
15
1
15
1,662
What should clinicians know about the updated @AmericanCancer prostate cancer screening guideline? 🎙️ Drs. Robert Smith and Andrew Wolf break down the major updates with our EIC Dr. Don Dizon in a new #CancerSpeak. Listen: cancerspeak.podbean.com/e/pr… @OncoAlert @ACSNews #PCSM
6
5
404
OncoAlert retweeted
My 2022 @JAMAOnc essay "Avoiding Checkmate", seems relevant for thinking into EGFR #lcsm Post-osi EGFRm NSCLC: ➡️ Ami-chemo approved (MARIPOSA-2) ➡️ Dato-DXd (AA) ➡️ Ivonescimab ❌, OS missed How do we plan line 3 at diagnosis? doi.org/10.1001/jamaoncol.20… @LungCancerRx @OncoAlert
4
9
1,121
OncoAlert retweeted
Hearing loss, tinnitus and vestibular dysfunction are easily overlooked among irAEs, yet can profoundly affect quality of life. Survival and survivorship go together. JIPO p.188 innovationsjournals-jipo.kgl… @HajjarJoud @BettzyStephen @ANaingMD @AAOHNS @OncoAlert #JIPO #ION
🤖 Made with AI
1
2
236
OncoAlert retweeted
📢 Happening Today | #SCLC Treatment in 2026–2027: What Is Changing? 📅 Today, 17 November 🕓 16:00–17:30 CET 👉 bit.ly/4ijiDMv #LungCancer #Radiotherapy #Radonc
3
6
639
An important question now is how best to position this combination in the treatment sequence. What will most influence its adoption in clinical practice? @OncoAlert
29%PFS benefit
33%Treatment sequencing
19%ESR1 testing
19%Mature OS data
21 votes • 9 hours
4
13
743
OncoAlert retweeted
New @Annals_Oncology study exploring ctDNA-guided pembro in resected dMMR tumours. - 92% 2-year RFS in MRD- without treatment - Despite ⬆️clearance in treated MRD+, 38% relapsed. Sustained clearance may be more informative @OncoAlert @YJanjigianMD annalsofoncology.org/article…
12
21
965
OncoAlert retweeted
🔬A randomized phase II trial found that adding toripalimab to modified FOLFIRINOX improved event-free survival in borderline resectable or locally advanced #PancreaticCancer. ➡️ Median EFS: 11.1 vs 9.6 months 🔸Tingbo Liang, MD, PhD | @JCO_ASCO 🔗 ascopost.com/news/november-2…
5
10
1,064